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Fixed Drug Eruption: A Rare Case of Polysensitivity between 
Two Unrelated Fixed Dose Combination Preparations - A Case 
Report 
Jessica Kaushal,1 Abhimanyu Rakesh.2 
Abstract 
Background: A fixed drug eruption is a type IV hypersensitivity reaction to a medication that characteristically re-emerges on the same site each time the 
specific drug is taken. Antimicrobials (including fixed dose combinations) are frequently implicated in fixed drug eruption while gliptins (as separate drugs 
or as combined preparations) on the other hand are infrequent triggers. Drugs belonging to similar classifications and having similar chemical structures 
can show cross reactivity, but here we describe a case of cross reactivity between unrelated drug classes, also known as polysensitivity. The Case: A 58-
year-old man presented with painful, burning, and pruritic blisters with ulcerations on the oral mucosa of his lips, hard palate, and tip of the tongue. The 
patient had been on vildagliptin - metformin fixed dose combination tablets for one year. He was asked to stop the drug and lesions started improving 
thereafter. A week later he suffered from gastroenteritis for which he took a combined preparation of ofloxacin - ornidazole and lesions re-appeared at 
the same site as before with severe itching and burning. Conclusion: This case highlights polysensitivity amongst chemically unrelated drugs, especially 
available in fixed dose combination. It is an extremely rare occurrence (less than 0.2%). Moreover, there have only been a few cases of such delayed 
reactions occurring to gliptins, especially vildagliptin. A clinician must keep a high index of suspicion to identify this phenomenon. 
 




Fixed drug eruption (FDE) is a cell mediated type IV hypersensitivity 
reaction frequently seen with antimicrobials, anticonvulsants and non-
steroidal anti-inflammatory drugs (NSAIDs).1 FDE is characterized by 
well-defined macular eruptions associated with blistering, burning or 
pruritis.1 Cross reactivity is frequently seen between drugs belonging 
to the same class. The lesions recur every time an offending agent is 
taken. Resolution of lesions is accompanied by a dusky pigmentation 
due to post-inflammatory disordered melanin distribution between 
keratinocytes. This hyperpigmentation is permanent in character.1 The 
condition becomes lifelong and avoidance of the offending agent is the 
key to management.1 
 
Type-2 diabetes mellitus is a prevalent chronic disease and the most 
common cause of significant morbidity around the world. Metformin, a 
biguanide, is the first line agent to which sulfonylureas (SUs) and 
dipeptidyl peptidase-4 inhibitors (DPP-4i) can be added as second line 
agents as the disease progresses.2 In the last decade, prescribing 
gliptins with metformin as an initial combination therapy is becoming 
a popular practice in India due to comparatively rapid achievement of 
target blood glucose levels with a negligible risk of hypoglycemia as 
the incretin effect of gliptins is glucose dependent.3  The additive effect 
of these two drugs also enhances insulin sensitivity.3 DPP-4i are more 
promising than SUs due to a better side effect profile along with better 
control on weight when added to metformin.4 Vildagliptin is a potent 
DPP-4i and is frequently prescribed in type-2 diabetics as an add on 
second line agent when the metformin monotherapy fails.5 Several 
adverse reactions have been attributed to this drug; however, reports 
regarding FDEs with gliptins have been very few to date.6 
 
In this case, the patient had already been on vildagliptin-metformin (V-
MF) 50mg/1000mg twice daily for almost one year when he started 
experiencing perioral itching with oral mucosal blistering and 
ulcerations. After identifying the potential of V-MF as a trigger for these 
reactions, the patient was asked to stop the drug, after which he 
achieved remission of his oral lesions. One week later, the patient was 
prescribed ofloxacin-ornidazole (OFL-ONZ) 200mg/500mg for an episode 
of gastroenteritis, and the re-emergence of similar oral lesions occurred 
at the same previously involved site but this time with exaggerated 
symptoms of itching, burning and blistering. This case is unique for not 
only reporting an infrequent adverse event associated with DPP-4 
inhibitors (gliptins) but also for focusing on polysensitivity of FDEs in 
chemically unrelated classes of medications, particularly those 
prescribed in fixed dose combination (FDC) tablets. The main aim of 
this article is to address an adverse event of polysensitivity which may 
be attributed to the common excipient used in the coating of these FDC 
tablets. 
Highlights: 
 Fixed drug eruption is a delayed type of hypersensitivity reaction. 
 Very few cases with vildagliptin have been reported; none has been 
reported with vildagliptin-metformin combination. 
 Cross reactivity seen between chemically different drugs exists 
(with emphasis of fixed dose combination drugs). 
 It may be plausible to hypothesize that the excipient titanium 
dioxide found in combined preparations could be the culprit. 
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A 58-year-old man presented in the clinic with chief complaints of 
itching, burning, and appearance of blisters and ulcerations with 
erythema on the oral mucosa of his lips, hard palate, and tip of the 
tongue for the past 2 days. The lesions appeared within 2-3 hours after 
consuming breakfast in the morning 2 days ago. The patient assumed 
the episode to be an allergic response to fruits he had consumed in his 
breakfast and decided to omit fruits in his following meals. He took 
fexofenadine hydrochloride, an over-the-counter antihistamine, for the 
lesions but there was no relief. The patient presented 2 days later due 
to persistence of these lesions despite the steps taken (Figure 1).  
 
He had no previous history of allergic reactions. Medical history was 
positive for diabetes mellitus type 2. He used to drink alcohol 
occasionally. Drug history included V-MF FDC oral preparation 
(50mg/1000mg, twice daily after meals) for the past year. He reported 
consuming the tablet from a new blister pack immediately after his 
breakfast a couple of days before presenting to the clinic. He continued 
to take the drug for the next 2 days as well. He was asked to 
discontinue the drug and follow up after 2 days. The patient claimed 
that he experienced relief in the following 48 hours after discontinuing 
the drug.  
 
An oral drug provocation test (DPT) was performed with V-MF full dose 
(1 tablet) which led to itching, burning and ulceration around the 
previous lesions. The positive test therefore supported the diagnosis of 
FDE due to this FDC drug. He switched to metformin and vildagliptin (as 
separate tablets) thereafter and did not have any problem. One week 
later, the patient experienced an episode of gastroenteritis with acute 
onset diarrhea for which he was administered OFL-ONZ, a FDC oral 
preparation containing ofloxacin (200mg) and ornidazole (500mg). Soon 
after this, there was recurrence of itching, erythema and burning 
around the lips. On discontinuation of OFL-ONZ, lesions started healing. 
Two days later, a DPT with half the dose of OFL-ONZ, the itching re-
emerged around the lips. The patient claimed no such reaction 
occurring with OFL-ONZ in the past. He was then advised to abstain 
from these as well as any FDC preparations in future. 
 
Two months after cessation of V-MF and refraining from FDC 
medications, the skin eruptions had subsided but there was a residual 
dark pigmentation on both the upper and lower lips where the original 
lesions had existed (Figure 2). 
 
Discussion 
Vildagliptin is a potent DPP-4i that prevents breakdown of endogenous 
incretins by DPP-4 enzyme thereby enhancing insulin secretion.  




Extensive monotherapy trials have shown improved glycemic regulation 
and substantial glycated hemoglobin (HbA1c) reductions in type-2 
diabetics along with a favorable adverse effect profile.7 These features 
make vildagliptin a propitious agent for combination therapies 
(especially with metformin) which has been evidenced through clinical 
trials.7 Metformin, a biguanide, has a different target of action. Both 
drugs are highly effective first line agents. Over time, regimens in 
diabetics require adjustments and new drug combinations to target 
different metabolic problems emerging within the body. FDCs help to 
simplify the already complex medication regimen in diabetics and helps 
improve patient compliance. 
 
The rationale behind combining fixed doses of two different drugs with 
different mechanisms of action is the benefit of an additive effect and 
a smaller number of individual doses required to achieve that effect.8 
As a result, vildagliptin (V) and metformin (MF) are frequently 
prescribed in FDCs (e.g. V-MF, an FDC drug combing these two salts in 
the ratio of 50mg:1000mg, respectively). V-MF is often prescribed twice 
daily along with non-pharmacological interventions such as lifestyle 
modifications (exercise, diet control) to keep blood sugar adequately 
controlled. Ofloxacin, a potent fluroquinolone is effective against gram-
negative and gram-positive bacteria covering both Staphylococcus 
Aureus and Pseudomonas Aeruginosa while ornidazole, a nitro 
imidazole derivative, is both an antibacterial and antiprotozoal. With a 
similar rationale, antimicrobials are also often prescribed in FDCs to hit 
several targets with a single dose and provide an additive effect. In 
addition, FDCs help to overcome antibiotic resistance and increase the 
antimicrobial spectrum.9 
 
Drug allergies can occur at any time. Here the patient developed a 
delayed-type hypersensitivity reaction after 1 year of taking V-MF FDC. 
An FDE is a type-IV hypersensitivity reaction to a medication, that 
characteristically re-emerges on the same site each time the drug is 
taken.10 Cross-reactivity between structurally or chemically similar 
drugs may occur. The lesions often involve the skin (trunk, limbs, etc.) 
and mucosal surfaces (lips, genitalia, perianal region) and may be 
localized or generalized. Healing begins once the offending agent is 
stopped, which is often followed by persistent dusky brown or purple 
post-inflammatory hyperpigmentation at the site of the reaction. This 
is called post-inflammatory hyperpigmentation that occurs once the 
inflammation subsides and is due to increased melanin production 
along with disordered distribution of melanin to the surrounding 
keratinocytes via melanosomes.11 There have been very few reports 
regarding FDEs secondary to gliptins and metformin.12 There has been 
no reported case of V-MF FDC drug-induced FDE to our knowledge. On 
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reported in the literature; however, polysensitivity (i.e. two structurally 
and chemically unrelated drugs inducing the same allergic reaction at 
the same site) has almost never been reported. Shiohara et al. once 
commented on an unusual case where polysensitivity was seen 
amongst three anticonvulsants.13 He proposed that such phenomenon 
exists frequently in reality but is under-reported due to lack of 
awareness and suspicion, and it is possible that polysensitivity is due 
to a non-antigen specific phenomenon.13 
 
In this case, the patient exhibited a polysensitivity phenomenon where 
two different FDC drugs induced hypersensitivity reactions at the same 
site. This was supported by the DPTs as well. DPT is the supervised 
administration of a suspected allergen to accurately diagnose 
hypersensitivity reactions. The patient did not experience any such 
reaction when individual drugs as separate salt-formulations were 
given. On reviewing the composition of all these drugs i.e., vildagliptin, 
metformin, their FDC preparation, ofloxacin, ornidazole and their FDC 
preparation, our attention was drawn towards the inactive inorganic 
ingredients. FDC drugs are usually coated with titanium dioxide 
nanoparticles (TiO2NPs) while the uncombined drugs come in an 
uncoated form. This has also been confirmed by spectroscopic 
studies.14 Titanium dioxide (TiO2) is a Food and Drug Administration 
approved food and pharmaceutical additive, mainly to confer white 
opaque coating to confectionaries, dairy products, and medicine 
tablets. TiO2NPs toxicity has not yet been established due to lack of 
sufficient research and reporting. TiO2, as a macroparticle or 
microparticle, is generally not harmful; however, toxicity due to TiO2 
nanoparticles is a novel concern in biomedical research. In a recent 
study it was said that nanoparticles (defined as particles with diameter 
<100 nm) become a health concern, especially if their size is 30 nm or 
less as they are not phagocytosed effectively by phagocytes, and can 
potentially trigger a pro-inflammatory cascade causing free radical 
injury.15 Also, a relatively small size of nanoparticles means higher 
surface area to volume ratio which potentially promotes nanoparticle 
deposition in tissues.15 As an opacifying pigment, TiO2 particle size 
spans over a range of 25 nm – 300 nm.16 Since TiO2 powders contain a 
variety of sizes, a fraction of nanoparticles does exist (which includes 
particles <30 nm in size) and it is roughly up to 36%.16  A review study 
by Skocaj et al. mentions that although TiO2NPs are considered safe, 
data on their toxic effects upon oral exposure has been very scarce. 
They propose that TiO2, when exposed to the acidic pH of the stomach, 
gets solubilized and disseminated via the blood and lymph into the 
different tissues especially the liver, spleen, kidneys and lungs.17 
Although the amount of TiO2 consumed via foods and medicines is far 
below the levels used for experimental studies that were reviewed to 
study the impact of TiO2NPs on the intestinal microenvironment and 
systemic immunoregulation,18 there still stands a possibility of the 
cumulative effect of TiO2 being consumed in small doses and therefore 
being accumulated constantly over long periods of time and triggering 




FDEs are infrequently associated with antidiabetic agents as very few 
cases have been reported and none have been reported with FDC 
preparation of vildagliptin and metformin to our knowledge. Healthcare 
providers should be aware of such rare adverse events with these 
drugs. Polysensitivity, especially amongst FDC preparations is possible. 
This case also discusses the possibility of TiO2 being a trigger antigen 
for type-IV hypersensitivity drug reactions as this patient experienced 
FDE with drugs containing TiO2 as an excipient (inactive ingredient), but 
did not experience a reaction when he consumed the same drugs in 
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